Cancer Supportive Care Market Share Analysis
The revenue share of the segment that sold granulocyte colony-stimulating factors, or G-CSFs, was greatest in 2022. It is the main therapy for neutropenia brought on by cancer. It is one among the medications used most frequently in supportive care for breast cancer and lymphoma.
The category with the most market share in 2022 was breast cancer. It is anticipated that demand for cancer supportive care medications would rise as a result of the necessity to control and lessen pain throughout the protracted breast cancer therapy.
In 2022, hospital pharmacies held the most share of the market. The hospital pharmacy's capacity to deliver patients individualised drug regimens for cancer patients is what is driving this market's growth. Additionally, it has been noted that the growing number of cancer patients being admitted to hospitals with advanced care settings is a key factor driving the expansion of the hospital pharmacy industry.